Cardio-targeted Transfer Factors

4Life Research holds the patent on extracting Transfer Factors from eggs. This proprietary technology is used to produce cardio-targeted Transfer Factors for the highly effective 4Life TFCardio product.

Leghorn hens are used to produce the eggs that contain cardio-targeted transfer factors. The hens are not battery-farmed, but are in a controlled and carefully-monitored environment to protect the hens from environmental pollutants.

They are treated like athletes - very well cared for, and given the best feed to concentrate their energy to produce the very best eggs.

The hens are not fed antibiotics, growth promoters, live vaccines, nor introduced to anything that could be detrimental to either the hens, or their production of exceptionally high-spec eggs.

To produce specific transfer factors in the eggs to target heart problems, the hens are gently and efficiently exposed to organism-markers known to cause heart disease. Their immune systems respond as would any human immune system by recognising the organism and creating the appropriate Transfer Factors to protect themselves and remain healthy.

The Transfer Factors produced are identical to those produced by cows (or other mammals) – the only difference being in the antigen-specific fraction that targets the heart diseases.

To make sure that the final product is live-organism-free and extremely safe for human consumption, the fluid contents from the eggs undergo specific FDA safety procedures, including a three-stage pasturisation process from which the Transfer Factors are then extracted.

This information based on an interview with Dr W Hennen, Ph.D, Chief Scientific Officer, 4Life Research